Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Werbrouck · SciRah

Researcher profile · Semantic Scholar

P. Werbrouck

Share profile

P. Werbrouck — researcher profile on SciRah

h-index: 14
Works: 39
Citations: 989

Most-cited papers

Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group.
H. Van Poppel, D. De Ridder, A. Elgamal, W. Van de Voorde +5 more
1995Journal of Urology176 citations
Semantic Scholar
FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
G. Swinnen, A. Maes, H. Pottel, A. Vanneste +3 more
2010European Urology163 citations
Semantic Scholar
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
J. de Bono, S. Chowdhury, S. Feyerabend, T. Elliott +6 more
2017European Urology111 citations Open access
Semantic Scholar
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
C. Sternberg, A. Armstrong, R. Pili, S. Ng +22 more
2016Journal of Clinical Oncology99 citations Open access
Semantic Scholar
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck +11 more
2014The Lancet Oncology96 citations
Semantic Scholar
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck +12 more
2015European Urology44 citations Open access
Semantic Scholar
Subjective, but not objective, cognitive complaints impact long-term quality of life in cancer patients
M. Lycke, Tessa Lefebvre, L. Pottel, H. Pottel +10 more
2019Journal of psychosocial oncology33 citations
Semantic Scholar
Long‐Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3‐Year Open Label Followup Results
B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck +9 more
2018Journal of Urology29 citations
Semantic Scholar
Predictors of baseline cancer‐related cognitive impairment in cancer patients scheduled for a curative treatment
M. Lycke, L. Pottel, H. Pottel, Lore Ketelaars +8 more
2017Psycho-Oncology29 citations Open access
Semantic Scholar
Validation of the Freund Clock Drawing Test as a screening tool to detect cognitive dysfunction in elderly cancer patients undergoing comprehensive geriatric assessment
M. Lycke, Lore Ketelaars, T. Boterberg, L. Pottel +11 more
2014Psycho-Oncology25 citations Open access
Semantic Scholar
The use of uHear™ to screen for hearing loss in older patients with cancer as part of a comprehensive geriatric assessment
M. Lycke, P. Debruyne, Tessa Lefebvre, E. Martens +11 more
2018Acta Clinica Belgica20 citations Open access
Semantic Scholar
Neoadjuvant treatment before radical prostatectomy decreases the number of positive margins in cT2-cT3 but has no impact on PSA progression or survival in cT2-T3
L. Baert, H. Goethuys, D. De Ridder, P. Werbrouck +3 more
199819 citations
Semantic Scholar
Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study.
Laura Tack, Tessa Lefebvre, M. Lycke, L. Pottel +13 more
2020Journal of Geriatric Oncology18 citations Open access
Semantic Scholar
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
A. Bjartell, Luís Costa, G. Kramer, B. Żurawski +13 more
2022European Urology Open Science15 citations Open access
Semantic Scholar
Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).
M. Smith, M. Borre, P. Rathenborg, P. Werbrouck +7 more
201314 citations
Semantic Scholar
The distress thermometer predicts subjective, but not objective, cognitive complaints six months after treatment initiation in cancer patients
M. Lycke, Tessa Lefebvre, L. Pottel, H. Pottel +9 more
2017Journal of psychosocial oncology12 citations Open access
Semantic Scholar
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
C. Van Praet, S. Rottey, Fransien Van Hende, G. Pelgrims +21 more
2016Urologic oncology12 citations Open access
Semantic Scholar
Which Factors Predict Overall Survival in Patients With Metastatic Castration‐Resistant Prostate Cancer Treated With Abiraterone Acetate Post‐Docetaxel?
C. Van Praet, S. Rottey, Fransien Van Hende, G. Pelgrims +21 more
2017Clinical Genitourinary Cancer10 citations Open access
Semantic Scholar
Recurrent flank pain caused by eosinophilic ureteritis mimicking urinary stone disease: A case report
G. Sergeant, K. Slabbaert, P. Werbrouck
2004International Urology and Nephrology10 citations
Semantic Scholar
Neoadjuvant Therapy Before Radical Prostatectomy: Impact on Progression Free Survival
H. Van Poppel, Hans Goethuys, D. De Ridder, P. Verleyen +4 more
200110 citations
Semantic Scholar
4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)
M. Carducci, A. Armstrong, R. Pili, S. Ng +16 more
20159 citations
Semantic Scholar
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
N. Shore, Christian Gratzke, S. Feyerabend, P. Werbrouck +23 more
2024The Oncologist7 citations Open access
Semantic Scholar
Balloon dilation of the prostate. Critical evaluation.
L. Baert, P. Werbrouck, B. Bamelis, H. van Poppel +1 more
1991Urologia internationalis6 citations
Semantic Scholar
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer.
Bertrand Tombal, M. Borre, P. Rathenborg, P. Werbrouck +6 more
2013Journal of Clinical Oncology5 citations
Semantic Scholar
Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.
B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck +10 more
20144 citations
Semantic Scholar
Hormonothérapie avant prostatectomie radicale. Effet sur l'acte chirurgical et les marges de résection
D. De Ridder, A. Elgamal, P. Werbrouck, K. Ackaert +4 more
19943 citations
Semantic Scholar
Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study.
J. de Bono, S. Chowdhury, S. Feyerabend, T. Elliott +6 more
20172 citations
Semantic Scholar
A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
G. Attard, A. Merseburger, C. Sternberg, L. Cerbone +14 more
20162 citations
Semantic Scholar
[Hormone therapy before radical prostatectomy. Effects on surgical method and resection margins. Belgian Uro-Oncological Study Group (B.U.O.S.)].
D. De Ridder, A. Elgamal, P. Werbrouck, K. Ackaert +4 more
1994Acta urologica Belgica2 citations
Semantic Scholar
Balloon dilatation of the external urethral sphincter: a case study.
P. Werbrouck, L. Baert, Joseph E. Binard, Rie K. Chiou +1 more
1990The Journal of The American Paraplegia Society2 citations
Semantic Scholar
630P Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial
C. Gratzke, K. Fizazi, N. Shore, M. Smith +11 more
2021Annals of Oncology1 citations Open access
Semantic Scholar
674 Enzalutamide monotherapy: Results from a phase 2 study in hormone naive prostate cancer patients
B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck +6 more
20131 citations
Semantic Scholar
Hormone treatment–related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study
K. Fizazi, N. Shore, M. Smith, J. Carles +12 more
2021European Urology0 citations
Semantic Scholar
Prostate cancer risk prediction using 5 different strategies: Independent validation in a Belgian cohort
S. Van Bruwaene, S. K. M. De Prycker, R. Veys, K. Lesage +4 more
2019European urology. Supplement0 citations
Semantic Scholar
Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results.
B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck +9 more
20170 citations
Semantic Scholar
772 Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?
C. Van Praet, S. Rottey, F. Van Hende, G. Pelgrims +21 more
20160 citations
Semantic Scholar
Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program.
S. Rottey, C. Van Praet, Fransien Van Hende, G. Pelgrims +16 more
20150 citations
Semantic Scholar
P060 Enzalutamide monotherapy in patients with hormone-naive prostate cancer: 1-year extended follow-up of a Phase 2 study
M. Borre, M. Smith, P. Rathenborg, P. Werbrouck +12 more
20140 citations
Semantic Scholar
P061 Efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer (HNPC)
H. Van Poppel, M. Smith, M. Borre, P. Rathenborg +7 more
20130 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Van Poppel×12
Invite
H. Van Poppel — researcher profile on SciRah
B. Tombal×10
Invite
B. Tombal — researcher profile on SciRah
M. Borre×10
Invite
M. Borre — researcher profile on SciRah
P. Rathenborg×10
Invite
P. Rathenborg — researcher profile on SciRah

×10

Invite

A. Heidenreich — researcher profile on SciRah

Invite

P. Iversen — researcher profile on SciRah

Invite

M. Smith — researcher profile on SciRah

E. Baskin-Bey×8

Invite

E. Baskin-Bey — researcher profile on SciRah

Invite

F. Perabo — researcher profile on SciRah

Invite

D. Phung — researcher profile on SciRah

Invite

H. Pottel — researcher profile on SciRah

Invite

M. Hirmand — researcher profile on SciRah